Biomarkers in Parkinson's disease: Advances and strategies

Marion Delenclos, Daryl R. Jones, Pamela J McLean, Ryan J. Uitti

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor disturbances and affects more than 1% of the worldwide population. Despite considerable progress in understanding PD pathophysiology, including genetic and biochemical causes, diagnostic approaches lack accuracy and interventions are restricted to symptomatic treatments. PD is a complex syndrome with different clinical subtypes and a wide variability in disorder course. In order to deliver better clinical management of PD patients and discovery of novel therapies, there is an urgent need to find sensitive, specific, and reliable biomarkers. The development of biomarkers will not only help the scientific community to identify populations at risk, but also facilitate clinical diagnosis. Furthermore, these tools could monitor progression, which could ultimately deliver personalized therapeutic strategies. The field of biomarker discovery in PD has attracted significant attention and there have been numerous contributions in recent years. Although none of the parameters have been validated for clinical practice, some candidates hold promise. This review summarizes recent advances in the development of PD biomarkers and discusses new strategies for their utilization.

Original languageEnglish (US)
Pages (from-to)S106-S110
JournalParkinsonism and Related Disorders
Volume22
DOIs
StatePublished - Jan 1 2016

Fingerprint

Parkinson Disease
Biomarkers
Neurodegenerative Diseases
Molecular Biology
Therapeutics
Population

Keywords

  • Biochemical biomarkers
  • Diagnosis
  • Imaging
  • Parkinson's disease
  • Progression

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Biomarkers in Parkinson's disease : Advances and strategies. / Delenclos, Marion; Jones, Daryl R.; McLean, Pamela J; Uitti, Ryan J.

In: Parkinsonism and Related Disorders, Vol. 22, 01.01.2016, p. S106-S110.

Research output: Contribution to journalArticle

Delenclos, Marion ; Jones, Daryl R. ; McLean, Pamela J ; Uitti, Ryan J. / Biomarkers in Parkinson's disease : Advances and strategies. In: Parkinsonism and Related Disorders. 2016 ; Vol. 22. pp. S106-S110.
@article{8852f4eb499c4607b50785361ecb7266,
title = "Biomarkers in Parkinson's disease: Advances and strategies",
abstract = "Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor disturbances and affects more than 1{\%} of the worldwide population. Despite considerable progress in understanding PD pathophysiology, including genetic and biochemical causes, diagnostic approaches lack accuracy and interventions are restricted to symptomatic treatments. PD is a complex syndrome with different clinical subtypes and a wide variability in disorder course. In order to deliver better clinical management of PD patients and discovery of novel therapies, there is an urgent need to find sensitive, specific, and reliable biomarkers. The development of biomarkers will not only help the scientific community to identify populations at risk, but also facilitate clinical diagnosis. Furthermore, these tools could monitor progression, which could ultimately deliver personalized therapeutic strategies. The field of biomarker discovery in PD has attracted significant attention and there have been numerous contributions in recent years. Although none of the parameters have been validated for clinical practice, some candidates hold promise. This review summarizes recent advances in the development of PD biomarkers and discusses new strategies for their utilization.",
keywords = "Biochemical biomarkers, Diagnosis, Imaging, Parkinson's disease, Progression",
author = "Marion Delenclos and Jones, {Daryl R.} and McLean, {Pamela J} and Uitti, {Ryan J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.parkreldis.2015.09.048",
language = "English (US)",
volume = "22",
pages = "S106--S110",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Biomarkers in Parkinson's disease

T2 - Advances and strategies

AU - Delenclos, Marion

AU - Jones, Daryl R.

AU - McLean, Pamela J

AU - Uitti, Ryan J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor disturbances and affects more than 1% of the worldwide population. Despite considerable progress in understanding PD pathophysiology, including genetic and biochemical causes, diagnostic approaches lack accuracy and interventions are restricted to symptomatic treatments. PD is a complex syndrome with different clinical subtypes and a wide variability in disorder course. In order to deliver better clinical management of PD patients and discovery of novel therapies, there is an urgent need to find sensitive, specific, and reliable biomarkers. The development of biomarkers will not only help the scientific community to identify populations at risk, but also facilitate clinical diagnosis. Furthermore, these tools could monitor progression, which could ultimately deliver personalized therapeutic strategies. The field of biomarker discovery in PD has attracted significant attention and there have been numerous contributions in recent years. Although none of the parameters have been validated for clinical practice, some candidates hold promise. This review summarizes recent advances in the development of PD biomarkers and discusses new strategies for their utilization.

AB - Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor disturbances and affects more than 1% of the worldwide population. Despite considerable progress in understanding PD pathophysiology, including genetic and biochemical causes, diagnostic approaches lack accuracy and interventions are restricted to symptomatic treatments. PD is a complex syndrome with different clinical subtypes and a wide variability in disorder course. In order to deliver better clinical management of PD patients and discovery of novel therapies, there is an urgent need to find sensitive, specific, and reliable biomarkers. The development of biomarkers will not only help the scientific community to identify populations at risk, but also facilitate clinical diagnosis. Furthermore, these tools could monitor progression, which could ultimately deliver personalized therapeutic strategies. The field of biomarker discovery in PD has attracted significant attention and there have been numerous contributions in recent years. Although none of the parameters have been validated for clinical practice, some candidates hold promise. This review summarizes recent advances in the development of PD biomarkers and discusses new strategies for their utilization.

KW - Biochemical biomarkers

KW - Diagnosis

KW - Imaging

KW - Parkinson's disease

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=84947867871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947867871&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2015.09.048

DO - 10.1016/j.parkreldis.2015.09.048

M3 - Article

C2 - 26439946

AN - SCOPUS:84947867871

VL - 22

SP - S106-S110

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -